Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

被引：0
|
作者：
Hui Yu
Ping Chen
Xiuyu Cai
Chen Chen
Xuanye Zhang
Lina He
Yixin Zhou
Shaodong Hong
Bei Zhang
机构：
[1] State Key Laboratory of Oncology in South China,Department of VIP Region
[2] Collaborative Innovation Center for Cancer Medicine,Department of Radiotherapy
[3] Sun Yat-Sen University Cancer Center,Department of Medical Oncology
[4] Sun Yat-Sen University Cancer Center,undefined
[5] Sun Yat-Sen University Cancer Center,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
PD-L1 inhibitors; PD-1 inhibitors; Small-cell lung cancer; First-line therapy; Efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：637 / 644
页数：7
相关论文
共 50 条
  • [41] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
    Jianfeng Peng
    Lemeng Zhang
    Liping Wang
    Hui Feng
    Dongmei Yao
    Rui Meng
    Xiaomei Liu
    Xiaohua Li
    Ningbo Liu
    Bingxu Tan
    Zhaoqin Huang
    Shanshan Li
    Xiangjiao Meng
    Radiation Oncology, 18
  • [42] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [43] The progress of PD-1 inhibitors in small-cell lung cancer
    Yang, Mengyuan
    Yuan, Ying
    Shen, Hong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (06): : 5523 - 5533
  • [44] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated
    Wang, Q.
    Xu, A.
    Ma, C.
    Wang, T.
    Liu, P.
    Duan, Y.
    Kong, T.
    Chen, G.
    Jia, X.
    Shang, K.
    Yang, G.
    Zhang, G.
    Yu, F.
    Wang, H.
    Chen, H.
    ANNALS OF ONCOLOGY, 2023, 34
  • [45] Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer
    Yu, L.
    Xu, J.
    Qiao, R.
    Zhong, H.
    Han, B.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S391 - S392
  • [46] Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis
    Ding, Jianqiao
    Liu, Zheyu
    Ning, Jing
    Sun, Nan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (03) : 259 - 267
  • [47] Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
    Jin, Chen-xing
    Liu, Yan-song
    Qin, He-nan
    Teng, Yi-bin
    Sun, Rui
    Ma, Zhong-jing
    Wang, A-man
    Liu, Ji-wei
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [48] Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study
    Peng, Yi
    Wu, De
    Tang, Jing
    Li, Xiaobing
    CANCER CONTROL, 2025, 32
  • [49] Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer
    Zhang, Dou
    Kong, Fanming
    Gao, Fangfang
    Li, Longhui
    Liang, Yangyueying
    Yu, Minghui
    Zhao, Lu
    Wang, Na
    Jia, Yingjie
    HELIYON, 2024, 10 (01)
  • [50] Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy
    Li, Lingling
    Pi, Chenghui
    Yan, Xin
    Lu, Jiangyue
    Yang, Xuhui
    Wang, Chunyu
    Li, Xiaoyan
    Zhang, Sujie
    Zhang, Zhibo
    Sun, Yi
    Hu, Yi
    FRONTIERS IN ONCOLOGY, 2021, 11
12345